Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook [Yahoo! Finance]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Yahoo! Finance
Pfizer ( NYSE:PFE ) is approaching a potentially important inflection point in its post-pandemic reset as early data from its Lyme disease vaccine trial begins to take shape, though the readout may leave room for debate. The company reported that its experimental shot, developed with Valneva, demonstrated 73% effectiveness against the tick-borne illness, but fewer-than-expected infections in the study made the overall efficacy harder to fully interpret. While the vaccine reduced cases among high-risk participants across the US, Canada, and Europe, the outcome did not fully align with expectations set before the trial, and a more comprehensive analysis is still ongoing ahead of planned regulatory submissions and scientific disclosure. Warning! GuruFocus has detected 6 Warning Signs with PFE. Is PFE fairly valued? Test your thesis with our free DCF calculator. The mixed nature of the results comes at a time when Pfizer is working to stabilize its growth profile after the Covid pe
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DCGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNGlobeNewswire
- Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results [Yahoo! Finance]Yahoo! Finance
- Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story [Yahoo! Finance]Yahoo! Finance
VALN
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form 20-F
- 3/10/26 - Form SCHEDULE
- VALN's page on the SEC website